Welcome to our dedicated page for Nkarta SEC filings (Ticker: NKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nkarta, Inc. (NASDAQ: NKTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nkarta is a clinical-stage biotechnology and biopharmaceutical company developing engineered, allogeneic, off-the-shelf NK cell therapies for autoimmune diseases, and its SEC filings offer structured insight into how it reports financial results, clinical progress, and key risks to investors.
Nkarta’s recent Form 8-K filings include press releases announcing quarterly financial results, where the company discusses research and development expenses, general and administrative expenses, net loss, and its cash position. These 8-Ks also reference Nkarta’s status as an emerging growth company and point to more detailed risk factor sections in its Form 10-K and Form 10-Q reports.
Through its periodic filings, Nkarta describes the clinical development of its lead NK cell therapy candidate NKX019, including its use in Ntrust-1 and Ntrust-2 autoimmune disease trials and investigator-sponsored studies. The company’s filings outline factors such as limited operating history, lack of approved products, dependence on NKX019, clinical trial timing, manufacturing complexity for CAR NK therapies, and reliance on third parties, which it identifies as key business and development risks.
On Stock Titan, Nkarta’s SEC filings are updated as new documents are posted to the EDGAR system. AI-powered summaries help explain the main points of lengthy filings, highlight changes from prior reports, and surface items such as financial condition discussions and risk factor updates. Users can quickly review 8-Ks related to earnings announcements and use the platform’s tools to understand how Nkarta’s disclosures connect to its NK cell therapy pipeline and autoimmune disease focus.
Nkarta, Inc. has filed a prospectus to offer up to $100,000,000 of its common stock in an at-the-market offering through Stifel, Nicolaus & Company, Incorporated pursuant to a Sales Agreement. The prospectus states the offering may occur from time to time at prevailing market prices and that Stifel may act as agent or, if authorized, as principal.
The cover cites a last reported sale price of $2.05 per share on March 24, 2026. The prospectus provides an illustrative post-offering share count of up to 120,070,977 shares assuming sales of 48,780,487 shares at $2.05. It also discloses a base outstanding share count of 71,078,531 as of December 31, 2025 and other outstanding counts shown with different as-of dates in the text.
Nkarta, Inc. entered into a Sales Agreement with Stifel, Nicolaus & Company for an at-the-market stock offering program. The company may sell, at its discretion, shares of common stock having an aggregate offering price of up to $100,000,000 through Stifel as sales agent.
The company will set sale parameters such as size, timing, daily limits and minimum prices, and will pay Stifel a commission of up to 3% of gross proceeds on shares sold. The shares will be issued under Nkarta’s effective Form S-3 registration statement and related at-the-market prospectus supplement filed with the SEC on March 25, 2026.
Nkarta, Inc. filed a shelf registration on Form S-3 to register up to $350,000,000 of securities, including an at-the-market program for up to $100,000,000.
The shelf prospectus describes offers of common stock, preferred stock, debt securities, warrants, rights and units that may be sold separately or together in one or more offerings. The at-the-market sales agreement with Stifel, Nicolaus & Company, Incorporated permits sales of up to $100,000,000 of common stock under an ATM; Stifel may act as agent or principal and may receive up to 3.0% of gross proceeds as compensation. The prospectus discloses 74,290,521 shares of common stock issued and outstanding as of March 18, 2026 (including 3,000,031 shares underlying pre-funded warrants) and notes that specific terms for each offering will be provided in prospectus supplements.
Nkarta, Inc. is a clinical-stage biopharmaceutical company developing allogeneic, off‑the‑shelf engineered NK cell therapies, led by NKX019, a CD19‑targeted CAR NK candidate for B‑cell–mediated autoimmune diseases such as lupus nephritis, primary membranous nephropathy, scleroderma, myositis and ANCA‑associated vasculitis.
NKX019 is in multiple Phase 1 trials (Ntrust‑1, Ntrust‑2) and investigator‑sponsored studies, supported by an internal CAR NK platform, cGMP manufacturing in South San Francisco and an extensive patent estate. The company has no approved products, has incurred significant losses and expects to need additional capital. As of June 30, 2025, equity held by non‑affiliates was valued at approximately $82.6 million, and as of March 18, 2026, there were 71,290,490 common shares outstanding.
Nkarta, Inc. reported fourth quarter and full year 2025 results and highlighted progress in its NKX019 autoimmune program. Cash, cash equivalents, restricted cash and investments totaled $295.1 million as of December 31, 2025, and are expected to fund operations into 2029.
For 2025, Nkarta recorded a net loss of $104.1 million, or $1.41 per share$90.4 million and general and administrative expenses were $31.6 million. Fourth quarter 2025 net loss was $27.4 million, or $0.37 per share.
Clinically, dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7, for a total of 12 billion cells per cycle in the Ntrust-1 and Ntrust-2 autoimmune trials. Initial clinical data from these trials are planned for presentation at a medical conference in 2026.
Tang Capital Management and related entities filed Amendment No. 2 to a Schedule 13G reporting their beneficial ownership in Nkarta, Inc. common stock. They report beneficial ownership of 1,480,823 shares, representing 2.1% of Nkarta’s common stock, based on 71,029,512 shares outstanding as of November 5, 2025. The shares are held with no sole voting or dispositive power and with shared voting and dispositive power over 1,480,823 shares across Tang Capital Management, Tang Capital Partners, Tang Capital Partners International and Kevin Tang. The filing states the securities were not acquired and are not held for the purpose of changing or influencing control of Nkarta, indicating a passive investment stance and confirming ownership of 5% or less of the class.
Nkarta, Inc. insider transaction: Chief Executive Officer and director Paul J. Hastings reported an automatic sale of 26,046 shares of Nkarta common stock on 01/15/2026 at a price of $2.07 per share. The filing explains that these shares were sold to satisfy tax withholding obligations arising from the vesting and settlement of Restricted Stock Units and that the transaction was not a discretionary trade by the reporting person. Following this tax-related sale, Hastings beneficially owned 390,023 shares of Nkarta common stock directly.
Nkarta, Inc. (NKTX) president Mahmood Nadir reported a small sale of company stock related to tax withholding. On January 15, 2026, he sold 5,649 shares of Common Stock at $2.07 per share. According to the footnote, these shares were sold solely to satisfy tax withholding obligations from the vesting and settlement of restricted stock units, and were not a discretionary sale. After this transaction, he directly beneficially owned 167,727 shares of Nkarta common stock.
Nkarta, Inc. insider Rose Shawn Marshall, the company’s Chief Medical Officer and Head of Research & Development, reported new equity awards on a Form 4. On January 6, 2026, Marshall received 70,000 shares of Common Stock in the form of Restricted Stock Units, granted at $0 per share. These RSUs vest in four equal annual installments beginning on January 14, 2027, with each RSU representing one share of Nkarta common stock.
On the same date, Marshall was also granted a stock option to buy 139,000 shares of Common Stock at an exercise price of $1.93 per share. This option is scheduled to vest in 48 equal monthly installments, based on continued service after January 14, 2026, and expires on January 5, 2036. Both awards are reported as directly owned following these transactions.
Nkarta, Inc. reported an equity award to its President, Mahmood Nadir, in the form of both restricted stock units and stock options. On 01/06/2026, he received 80,000 shares of Common Stock as Restricted Stock Units, which are scheduled to vest in four equal annual installments beginning on January 14, 2027. Each RSU represents a contingent right to receive one share of Common Stock.
On the same date, he was also granted a stock option covering 160,000 shares of Common Stock at an exercise price of $ 1.93 per share, expiring on 01/05/2036. This option is scheduled to vest in 48 equal monthly installments following January 14, 2026, contingent on continued service. After these transactions, he directly beneficially owned 173,376 shares of Common Stock and 160,000 derivative securities.